STOCK TITAN

Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of Celldex Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 5,322,908 shares, representing 6.78% of Celldex’s outstanding common stock, with no sole voting or dispositive power reported for any of the filers.

Positive

  • None.

Negative

  • None.
Beneficial ownership percentage 6.78% Percent of Celldex Therapeutics common stock reported as beneficially owned
Shares with shared voting power 5,322,908 shares Shares over which the reporting persons have shared power to vote or direct the vote
Shares with shared dispositive power 5,322,908 shares Shares over which the reporting persons have shared power to dispose or direct disposition
Par value of common stock $0.001 Par value per share of Celldex Therapeutics common stock
CUSIP 15117B202 CUSIP number for Celldex Therapeutics common stock
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 0"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 5,322,908.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 5,322,908.00"
percent of class financial
"Percent of class: 6.78 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

What percentage of Celldex Therapeutics (CLDX) does Kynam Capital report owning?

Kynam Capital and related reporting persons report beneficial ownership of 6.78% of Celldex Therapeutics’ common stock, based on shared voting and dispositive power over 5,322,908 shares as described in the ownership section.

How many Celldex Therapeutics (CLDX) shares does Kynam Capital control?

The filing states that Kynam Capital, its GP entity, and Yue Tang have shared voting and dispositive power over 5,322,908 shares of Celldex Therapeutics common stock, corresponding to 6.78% of the class.

Who are the reporting persons in this Celldex (CLDX) ownership filing?

The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. Each reports shared voting and dispositive power over 5,322,908 shares of Celldex common stock, with no sole voting or dispositive power.

Does Yue Tang have sole voting power over any Celldex (CLDX) shares?

No. The filing states that Yue Tang has 0 shares with sole voting power and 5,322,908 shares with shared voting power. The same figures apply to shared dispositive power over Celldex common stock.

What class of Celldex (CLDX) securities is reported as owned by Kynam Capital?

The ownership relates to Celldex Therapeutics’ Common Stock, par value $0.001, identified by CUSIP 15117B202. The reporting group has shared voting and dispositive power over 5,322,908 shares of this class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





15117B202

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Kynam Capital Management, LP
Signature:Yue Tang
Name/Title:Managing Member
Date:08/14/2026
Kynam Capital Management GP, LLC
Signature:Yue Tang
Name/Title:Managing Member
Date:08/14/2026
Yue Tang
Signature:Yue Tang
Name/Title:Self
Date:08/14/2026